Skip to main content
. 2021 Nov 6;9(31):9333–9349. doi: 10.12998/wjcc.v9.i31.9333

Figure 2.

Figure 2

Schematic summary of the pharmaconutrition strategy and possible outcomes: ⊗ - Disconnecting bi-directional relationship between severe acute respiratory syndrome coronavirus 2 and non-alcoholic fatty liver disease and ↓ - decrease. ω-3 LCPUFA: Omega-3 long-chain polyunsaturated fatty acids; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; NAFLD: Non-alcoholic fatty liver disease; COVID-19: Coronavirus disease 2019.